Transgene announces detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers
By @CcR34Tg|2020-10-26T18:53:22+01:00October 27th, 2020|Press release, TG4001, TG4001|Comments Off on Transgene announces detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers
About the Author: @CcR34Tg
Related Posts
- Transgene presents e-poster outlining detailed results from the Phase 1b/2 trial of TG4001 in combination with avelumab in advanced HPV-positive cancers at SITC 2020
Transgene presents e-poster outlining detailed results from the Phase 1b/2 trial of TG4001 in combination with avelumab in advanced HPV-positive cancers at SITC 2020
- TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16+ cancers: clinical efficacy and immunogenicity
TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16+ cancers: clinical efficacy and immunogenicity